GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

This looked at patients with transplant-eligible newly diagnosed multiple myeloma ... survival [PFS], as well as overall ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

Multiple Myeloma is a type of blood cancer that develops in plasma ... can provide patients with extended survival and ...

CAR T-cell therapies for hematologic malignancies have targets that are found primarily in blood, lymph nodes, and bone ...

SEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCLCoverage leverages new Medicare episode pricing ...

Overall response rate (ORR): percentage ... control and longer survival, he explained. Fung is the chair of the Department of Bone Marrow Transplant and Cellular Therapies and director of the Multiple ...

Sharda Sinha's battle with Multiple Myeloma highlights the disease's dangers. Learn about its impact and significance.- Watch ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.